07 Jan 2001

Paspat® (Paspat® Injektionslösung i.c., skar.) - Deutschland

Updated: 07 Jan 2001


Asthmoide Bronchitis; allergische Rhinitis, Otitis, Sinusitis; Conjunctivitis vernalis; erhöhte Infektanfälligkeit.

Paspat® Description, Presentation and Dosage

Paspat® Description

Paspat® Drug Class Description

Kombinationen mit Mikroorganismen-haltigen Präparaten

Paspat® Drug Description

0,2 ml enth.: Autolysate von: Staphylococcus aur. Staphylococcus alb. Streptococcus virid. Streptococcus haemolyt. Diplococcus pneumon. Neisseria catarrhal. Haemophilus influenzae, Candida albic.

Paspat® Generic Name

Paspat® Injektionslösung i.c., skar.

Paspat® Presentation

Paspat® Presentation


Paspat® Manufacturer


Related Learning Zones

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Oral Anticoagulation Reversal Knowledge Centre

Oral Anticoagulation Reversal Knowledge Centre

The Oral Anticoagualtion Reversal Knowledge Centre is intended to provide healthcare professionals with accurate information on the approaches to oral anticoagulation reversal for patients who experience or are at risk of significant bleeding, or require surgery. Content is arranged within illustrated and referenced sections including management of bleeding risk, oral anticoagulants, symposium highlights, key publication summaries and more.

This resource is developed by EPG Health Media (Europe) Ltd for epgonline.org in collaboration with CSL Behring, with content provided by CSL Behring.

This resource is not intended for healthcare professionals outside Europe.

Paspat® Dosage

Paspat® Adult Dosage

Glycerol, Natriumchlorid, Wasser f. Inj.-zwecke.

Paspat® Precautions, Reactions and Contraindications

Paspat® Special Precautions

Paspat® Special Precautions

Akute Infekte, chron. Organprozesse wie Hepatitis od. Nephritis, floride Endokarditis, asthmoide Zustände b. Herzmuskel- u. Herzklappenerkrankungen, schweres Asthma (kortikoidpflichtig), Raucherbronchitis, konsumierende Erkrankungen, Tuberkulose, gleichz. Therapie m. Immunsuppressiva u. weiteren Medikamenten m. immunsuppressiver Wirkung, Komb. m. anderen Immunstimulanzien, Antigengemischen od. Impfstoffen (keine ausr. Erfahr.), Autoimmunkrankheiten, Immundefekt-Syndrome wie z. B. AIDS od. Leukämie.

Paspat® Adverse Reactions

Paspat® Adverse Reactions

Kontraind. i. 1. Trim. Strenge Ind.-Stellung im 2. u. 3. Trim. Gr 5 .

Related Drugs - Allergy/Clinical Immunology

Back to top